Make your own free website on Tripod.com

Hematology Center
Prothrombin 20210A

Home

Bleeding Patient
Reversing Coumadin
Reversing Heparin
Laboratory Tests in Hematology
Laboratory Tests In Coagulation
Aceruloplasminemia
African Iron Overload
Anemia, microcytic
Antiphospholipid Syndrome
Anemia, Microcytic, real cases
ATIII Deficiency
Atransferrinemia
Aplastic Anemia
B12 deficiency
Basophilia
Coagulation and Cancer
DIC
Essential Thrombocytosis
ENZYME DISORDERS (RBC)
Eosinophilia
Folate Deficiency
Hemoglobinoapthies
Hemoglobin S/C
Hemoglobin S/S
Hemolytic Anemia
Hemochromatosis
Hemophilia
Hemostasis
Heparins
Heparin-induced thrombocytopenia
Hypercoagulable States
Hyper-Ferritinemia
ITP
Iron Chelation
IRON DEFICIENCY
IRON OVERLOAD
IRON STUDIES
Liver and hemostasis
Megaloblastic Anemia
Monocytosis
Myleofibrosis with Myeloid Metaplasia
Neutrophil Structure
vWF
Porphyria
Phorphyrias (AIP)
Phorphyrias (AIP)
Polycythemia Vera
Prothrombin 20210A
RBC Membrane Disorders
Sickle Cell
Sideroblastic Anemias
Syndromes
TTP
Thalassemia
Thrombocytopenia, congenital
Wilson's Disease
Immunological markers
Amicar
Anagrelide
Oral Anticoagulants
Refludan


Prothrombin 20210A

One of the newest detected causes of hypercoagulability is prothrombin 20210A allele, an abnormality described in 1996.

Frequency of this abnormality varies from 0.7% to 6.0% among whites, with rare appearances among Africans and Asians, suggesting that the defect may have also appeared after the divergent migrations of the populations.

The combination of prothrombin 20210A with other defects such as factor V Leiden, protein S deficiency, protein C deficiency, or antithrombin deficiency has been reported.

The mechanism by which prothrombin 20210A allele is responsible for hypercoagulability is uncertain.